Treatment of anaemia of CKD is guided by data from randomised trials of ESAs, which demonstrated that normalisation of haemoglobin (Hb) levels (13.0–15.0 g/dl) did not reduce cardiovascular events compared with a lower target range (10.5–11.5 g/dl) [20]. This evidence concerns the gene GSTM1 and chronic kidney disease.